The ethical issues surrounding orders not to resuscitate are complex and increasingly a matter for legislative acts and judicial decisions."I 13 Furthermore, decisions on resuscitation have implications for resource management. Despite these issues "Do not resuscitate" orders in many British hospitals are used without guidelines and without assessment of their effectiveness in preventing futile cardiopulmonary resuscitation.
Abstract
Objective-To see whether parathyroid hormone related protein has a humoral role in breast cancer.
Design-Plasma concentrations and tumour expression of parathyroid hormone related protein were determined (by two site immunoradiometric assay and immunohistochemistry respectively) in women with breast cancer and related to the presence of bone metastases and serum calcium concentrations.
Subjects-Plasma concentrations of parathyroid hormone related protein were measured in 57 women with early breast cancer without apparent bone metastases, 28 women with bone metastases, and 13 women with bone metastases and hypercalcaemia. Tissue positivity for parathyroid hormone related protein was determined retrospectively in 106 primary breast tumours from women without apparent bone metastases and 72 tumours from women with bone metastases, 25 of whom subsequently developed hypercalcaemia.
Results-Plasma parathyroid hormone related protein concentrations were detectable. (>0.23 pmol/l) in 12 (92%) of the 13 hypercalcaemic patients with bone metastases compared with 10 (36%) of the 28 normocalcaemic patients with bone metastases and five (9%) of the 57 normocalcaemic patients without bone metastases. Parathyroid hormone related protein concentrations were significantly higher in hypercalcaemic than normocalcaemic patients with bone metastases. Tumour staining was positive for parathyroid hormone related protein in
Introduction
Hypercalcaemia is a common complication of malignancy. In patients with breast cancer it has traditionally been attributed to skeletal metastases and local osteolysis by tumour derived factors such as interleukin 1, prostaglandins, and tumour necrosis factor.' 2 There is little evidence that these factors cause hypercalcaemia when introduced by injection, and it is assumed that their actions are largely paracrine, involving localised destruction of bone. The biochemical changes seen in some patients with hypercalcaemia and breast cancer are well documented and include increased renal tubular reabsorption of calcium, a decrease in the renal tubular threshold for phosphate reabsorption, and increased excretion of nephrogenous cyclic AMP.34 These abnormalities are consistent with the actions of a tumour derived parathyroid hormone-like factor with effects on both kidney and bone and have led to the hypothesis that the mechanism of hypercalcaemia in breast cancer is mediated humorally by a parathyroid hormone-like peptide. 45 Parathyroid hormone related protein is a hypercalcaemic factor with similar bioactivity to that of parathyroid hormone. Since its isolation in 1987 from cancer cell lines and a carcinoma of the breast,6 strong evidence has accumulated that parathyroid hormone related protein is an important humoral mediator of cancer associated hypercalcaemia in patients with solid tumours, typically squamous carcinoma of lung.78
We have investigated the possibility that parathyroid hormone related protein has a humoral role in breast cancer by comparing plasma concentrations and tumour expression of parathyroid hormone related protein in patients with different serum calcium concentrations and metastatic status.
Patients and methods
The following groups of breast cancers were studied by immunohistochemistry for parathyroid hormone related protein: (a) 72 tumours from normocalcaemic women in whom bone was the initial site of metastatic recurrence (a subset of 25 of these patients subsequently developed hypercalcaemia ("corrected" calcium range 2-7-3-9 mmol/l)); and (b) 106 consecutive tumours from normocalcaemic women with early breast cancer and no obvious metastatic disease.
Plasma parathyroid hormone related protein was measured by two site immunoradiometric assay in the following groups of women with breast cancer: (a) hypercalcaemic women with bone metastases (n= 13; corrected calcium range 2-69-4-07 mmol/1); (b) normocalcaemic women with bone metastases (n=28); and (c) normocalcaemic women with early operable breast cancer without apparent bone metastases (n= 57).
Tumour tissue for immunohistochemistry was available from five patients with hypercalcaemia.
IMMUNOHISTOCHEMISTRY
For immunohistochemistry all tissue samples were fixed in 4% formaldehyde in saline and routinely processed to paraffin blocks. The primary antiserum was raised in a rabbit to the mid-region sequence of parathyroid hormone related protein (amino acids 37-67); this antiserum cross -reacts with both native and synthetic forms of parathyroid hormone related protein but not parathyroid hormone. 9 After dewaxing of the section non-specific binding sites were blocked with non-immune swine serum diluted 1/5 for 10 minutes. Excess serum was removed and the primary antiserum diluted 1/100 applied for one hour at room temperature. This was followed by application of biotinylated swine antirabbit immunoglobulin antiserum and streptavidin-biotin peroxidase complex (both Dako Ltd, High Wycombe, Buckinghamshire) and washing in TRIS hydrochloride buffer (pH 7 6). Peroxidase was localised with diaminobenzidinehydrogen peroxide and nuclei counterstained with Mayer's haematoxylin.
Controls for immunohistochemistry included omission of the primary antibody and preincubation of the primary antibody with parathyroid hormone related protein 37-67 (0-5 g/l) for 16 dent observers who were blind to the identity of the patient and the presence or absence ofhypercalcaemia. When interpretation differed further slides were stained until agreement was achieved. Only cytoplasmic reactivity was considered positive.
PLASMA ASSAYS
Plasma parathyroid hormone related protein 1-86 concentrations were measured by a two site immunoradiometric assay.9 Concentrations are undetectable (-0 23 pmol/l) in normocalcaemic controls and detectable in most patients with hypercalcaemia associated with various solid tumours other than breast cancer.9 Plasma parathyroid hormone 1-84 concentrations (reference range 9-40 ng/l) were measured by "N-tact" immunoradiometric assay (INCSTAR, Wokingham, Berkshire).
Results
Positive cytoplasmic staining for parathyroid hormone related protein was found in 55 (52%) of the 106 early breast cancers (fig 1) . The proportion of cells staining in individual tumours varied, with additional variation in intensity, while surrounding stromal tissue Was consistently negative. Positive staining was abolished by omission of the primary antiserum and absorption of antiserum by parathyroid hormone related protein 37-67. In the group in whom tumour first recurred in bone positive staining was found in 47 (65%) of the 72 primary tumours. Positive immunostaining for parathyroid hormone related protein occurred in 22 (88%) primary tumours from the 25 women who developed hypercalcaemia compared with 25 (53%) tumours from the 47 women who remained normocalcaemic (p=0 004; Fisher's exact test). All 22 tumours from patients with serum calcium concentrations >2-9 mmol/l showed positive staining for parathyroid hormone related protein, while the three with negative staining were from patients with lower serum calcium concentrations (2-7, 2 7, and 2-9 mmol/1).
Parathyroid hormone related protein 1-86 was detectable in the plasma in five of 57 patients (9%) with early breast cancer without known metastases (mean 0-33 pmol/l; range 0-25-0-46 pmol/l) and in 10 of 28 patients (36%) with bone metastases (mean 0 59 pmol/l; range 0-23-1-50 pmol/l). In nine of this second group ofpatients with detectable parathyroid hormone related protein in whom parathyroid hormone 1-84 concentrations were measured the mean concentration was 23 (range 8-32) ng/l. Plasma parathyroid hormone related protein 1-86 was detectable in 12 of 13 (92%) patients (mean 3.7 pmol/l; range 0-54-8-1 pmol/l) with hypercalcaemia and in significantly higher concentrations than in patients with early breast cancer (p<001) or in normoc'alcaemic patients with bone metastases (p<0001; Mann-Whitney U test) (fig 2) . Plasma parathyroid hormone 1-84 concentrations were measured in nine hypercalcaemic patients and were <5 ng/l in four; the remaining five had a mean concentration of 11 (range 7-17) ng/l. Positive immunostaining was found in all five tumours examined from women with hypercalcaemia and increased plasma parathyroid hormone related protein 1-86 concentrations.
Discussion
This systematic study of tissue and plasma parathyroid hormone related protein in women with breast cancer and hypercalcaemia has shown a clear gradation in the frequency of positive cytoplasmic staining for parathyroid hormone related protein in breast cancer, the lowest frequency being in tumours without associated metastatic disease and the highest in tumours associated with hypercalcaemia and bone metastases.
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